An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
Welcome to the calm before the Covid-19 storm.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Big pharma pipelines are getting smaller, but novel medicines are being tested in more indications than ever before, a new analysis finds.
The pandemic prompts only a slight drop in medtech approvals.
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
An across-the-board clinical trial registry analysis spells out the effect of measures to slow the spread of the new coronavirus.